Literature DB >> 29730198

Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.

Rebecka Arnsrud Godtman1, Max Schafferer2, Carl-Gustaf Pihl2, Johan Stranne2, Jonas Hugosson2.   

Abstract

PURPOSE: We sought to determine long-term outcomes after deferred radical prostatectomy.
MATERIALS AND METHODS: The study population consisted of all 132 men with screening detected prostate cancer who underwent deferred radical prostatectomy from January 1, 1995 to December 31, 2014 after active surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial. The last date of followup was May 15, 2017. Followup during active surveillance was performed with prostate specific antigen tests every 3 to 6 months and repeat biopsies every 2 to 4 years. Triggers for radical prostatectomy were disease progression based on prostate specific antigen, grade and/or stage, or patient request. Outcomes included adverse pathology findings at radical prostatectomy, defined as Gleason score greater than 3 + 4, extraprostatic extension, positive margins, seminal vesicle invasion and/or N+, whether the index tumor at radical prostatectomy was identified at biopsy and prostate specific antigen relapse-free survival. Kaplan-Meier analysis was performed.
RESULTS: Median time from diagnosis to surgery was 1.9 years (IQR 1.2-4.2) and median postoperative followup was 10.9 years (IQR 7.5-14.5). A total of 52 men (39%) experienced at least 1 unfavorable pathology feature at radical prostatectomy. The 10-year prostate specific antigen relapse-free survival was 79.5%. The index tumor was not identified in the diagnostic biopsy in 38 of the 132 men (29%) or at the last repeat biopsy that preceded radical prostatectomy 22 of 105 (21%).
CONCLUSIONS: A large proportion of men had unfavorable pathology findings at deferred radical prostatectomy and the index tumor was frequently not identified. There is a clear need for better risk classification and protocols to determine disease progression during active surveillance.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  disease progression; mass screening; prostatectomy; prostatic neoplasms; watchful waiting

Mesh:

Substances:

Year:  2018        PMID: 29730198     DOI: 10.1016/j.juro.2018.04.078

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.

Authors:  Yoichiro Tohi; Takuma Kato; Masaki Nakamura; Ryuji Matsumoto; Hiroshi Sasaki; Koji Mitsuzuka; Junichi Inokuchi; Katsuyoshi Hashine; Akira Yokomizo; Hirohito Naito; Isao Hara; Norihiko Kawamura; Masaharu Inoue; Hiroshi Fukuhara; Satoru Maruyama; Shinichi Sakamoto; Toshihiro Saito; Shin Egawa; Yoshiyuki Kakehi; Mikio Sugimoto
Journal:  Int J Clin Oncol       Date:  2021-10-02       Impact factor: 3.402

2.  Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform.

Authors:  Katharina Beyer; Vera Straten; Sebastiaan Remmers; Steven MacLennan; Sara MacLennan; Giorgio Gandaglia; Peter-Paul M Willemse; Ronald Herrera; Muhammad Imran Omar; Beth Russell; Johannes Huber; Markus Kreuz; Alex Asiimwe; Tom Abbott; Alberto Briganti; Mieke Van Hemelrijck; Monique J Roobol
Journal:  J Pers Med       Date:  2022-05-05

3.  Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.

Authors:  Ekaterina Laukhtina; Reza Sari Motlagh; Keiichiro Mori; Fahad Quhal; Victor M Schuettfort; Hadi Mostafaei; Satoshi Katayama; Nico C Grossmann; Guillaume Ploussard; Pierre I Karakiewicz; Alberto Briganti; Mohammad Abufaraj; Dmitry Enikeev; Benjamin Pradere; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-05-28       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.